Astellas files for approval of extended-release quetiapine in Japan

10 August 2016
astellas-logo-big

Japanese drug major Astellas Pharma (TYO: 4503) has submitted a new drug application to the Ministry of Health, Labor and Welfare in Japan for extended-release tablets of quetiapine fumarate (FK949E) for the indication of improvement of depressive symptoms associated with bipolar disorder.

Astellas has a license agreement with Anglo-Swedish peer AstraZeneca (LSE: AZN) that provides it with exclusive rights in Japan to develop and commercialize extended-release tablets of quetiapine fumarate, AstraZeneca’s now off-patent once-daily blockbuster drug Seroquel XR.

This application is based primarily on the results of a Phase-III clinical trial consisting of a placebo-controlled, double-blind, comparative study and an extension study, to confirm the efficacy and safety of extended-release tablets of quetiapine fumarate, administered orally once daily to Japanese patients diagnosed with bipolar depression. The program started following a development request from the Evaluation Committee on Unapproved or Off-label Drugs with High Medical Needs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical